Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.
The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nH...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5963779?pdf=render |
| _version_ | 1830511707112341504 |
|---|---|
| author | Angelika Chachaj Jerzy Wiśniewski Justyna Rybka Aleksandra Butrym Monika Biedroń Małgorzata Krzystek-Korpacka Mariusz Grzegorz Fleszar Maciej Karczewski Tomasz Wróbel Grzegorz Mazur Andrzej Gamian Andrzej Szuba |
| author_facet | Angelika Chachaj Jerzy Wiśniewski Justyna Rybka Aleksandra Butrym Monika Biedroń Małgorzata Krzystek-Korpacka Mariusz Grzegorz Fleszar Maciej Karczewski Tomasz Wróbel Grzegorz Mazur Andrzej Gamian Andrzej Szuba |
| author_sort | Angelika Chachaj |
| collection | DOAJ |
| description | The study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5-53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58-5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91-11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients. |
| first_indexed | 2024-12-22T02:16:37Z |
| format | Article |
| id | doaj.art-27436627cf00434f806cab9d447a1a14 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T02:16:37Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-27436627cf00434f806cab9d447a1a142022-12-21T18:42:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019714810.1371/journal.pone.0197148Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.Angelika ChachajJerzy WiśniewskiJustyna RybkaAleksandra ButrymMonika BiedrońMałgorzata Krzystek-KorpackaMariusz Grzegorz FleszarMaciej KarczewskiTomasz WróbelGrzegorz MazurAndrzej GamianAndrzej SzubaThe study was designed to determine the associations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginines plasma concentrations with all-cause mortality in patients with hematological malignancies. 33 patients with acute myeloid leukemia (AML), 31 patients with non-Hodgkin's lymphoma (nHL), 32 patients with chronic lymphocytic leukemia (CLL) and 48 patients without malignancy were enrolled into the study. Each patient was followed until death or for at least 14.5 months (range: 14.5-53). Median ADMA and SDMA were significantly elevated in AML, nHL and CLL compared to controls (ADMA: 1.36, 1.24, 1.03, 0.55 μmol/l respectively, p<0.0001; SDMA: 0.86, 0.76, 0.71, 0.52 μmol/l respectively, p<0.0001). High ADMA and SDMA were associated with increased risk for all-cause mortality in CLL group (Hazard ratio (HR) for ADMA: 3.05, 95% CI:1.58-5.88, p = 0.001; HR for SDMA: 4.71, 95% CI:1.91-11.58, p = 0.001). Our study suggests that ADMA and SDMA could be novel prognostic factors for all-cause mortality in CLL patients.http://europepmc.org/articles/PMC5963779?pdf=render |
| spellingShingle | Angelika Chachaj Jerzy Wiśniewski Justyna Rybka Aleksandra Butrym Monika Biedroń Małgorzata Krzystek-Korpacka Mariusz Grzegorz Fleszar Maciej Karczewski Tomasz Wróbel Grzegorz Mazur Andrzej Gamian Andrzej Szuba Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study. PLoS ONE |
| title | Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study. |
| title_full | Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study. |
| title_fullStr | Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study. |
| title_full_unstemmed | Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study. |
| title_short | Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study. |
| title_sort | asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies a prospective study |
| url | http://europepmc.org/articles/PMC5963779?pdf=render |
| work_keys_str_mv | AT angelikachachaj asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT jerzywisniewski asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT justynarybka asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT aleksandrabutrym asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT monikabiedron asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT małgorzatakrzystekkorpacka asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT mariuszgrzegorzfleszar asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT maciejkarczewski asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT tomaszwrobel asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT grzegorzmazur asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT andrzejgamian asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy AT andrzejszuba asymmetricandsymmetricdimethylargininesandmortalityinpatientswithhematologicalmalignanciesaprospectivestudy |